SCHEMBL6766379

SCHEMBL6766379

O=C(O)C1(NS(=O)(=O)c2ccc(-c3ccc(Br)cc3)cc2)CCCC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ MMP1 P03956 12/20 0.51
▸ MMP13 P45452 12/20 0.51
▸ MMP2 P08253 10/20 0.51
▸ MMP9 P14780 8/20 0.51
▸ MMP3 P08254 7/20 0.51
▸ MMP7 P09237 7/20 0.51
▸ MMP14 P50281 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ ITGB1 P05556 2/20 0.45
▸ ITGA4 P13612 2/20 0.45
▸ PLG P00747 2/20 0.44
▸ PLAU P00749 2/20 0.44
▸ PLAT P00750 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ MMP8 P22894 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6770734 0.99 USP2 (0.56) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL7064268 0.94 HTT (0.60) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL6772246 0.87 MMP1 (0.62) MMP1MMP13MMP2MMP9MMP3
SCHEMBL12418068 0.87 MMP1 (0.47) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL7066967 0.87 HTT (0.59) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL6777252 0.86 MMP1 (0.62) MMP1MMP13MMP2MMP9MMP3
SCHEMBL12418064 0.85 MMP1 (0.47) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL14676227 0.82 USP2 (0.58) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL5675304 0.80 USP2 (0.60) USP2HTTSMN1; SMN2MMP1MMP13
SCHEMBL7065804 0.79 SMN1; SMN2 (0.60) USP2HTTSMN1; SMN2MMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1210326-A2 HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-06-05 — — EP claimed
WO-2001012592-A2 HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-02-22 — — WO claimed
US-9616037-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2017-04-11 — — US disclosed
US-9616037-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2017-04-11 — — US disclosed
US-20160206578-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2016-07-21 — — US disclosed
US-20160206578-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2016-07-21 — — US disclosed
US-9302984-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2016-04-05 — — US disclosed
US-9302984-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2016-04-05 — — US disclosed
US-20150266815-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2015-09-24 — — US disclosed
US-20150266815-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2015-09-24 — — US disclosed
US-9050329-B1 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2015-06-09 — — US disclosed
US-20130245018-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (US) 2013-09-19 — — US disclosed
US-8435968-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2013-05-07 — — US disclosed
US-8435968-B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use PIMCO 2664 LIMITED (GB) 2013-05-07 — — US disclosed
US-20110172189-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2011-07-14 — — US disclosed
US-20110172189-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use PIMCO 2664 LIMITED (GB) 2011-07-14 — — US disclosed
WO-2010032009-A1 ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE PIMCO 2664 LIMITED (GB) 2010-03-25 — — WO disclosed
US-6677355-B1 DIBENZOFURAN-3-(SULFONYLAMINO OR SULFINAMINO) DERIVATIVES; MULTIPLE SCLEROSIS, ATHEROSCLEROSIS, HEART FAILURE, PERIODONTAL DISEASE, OSTEOARTHRITIS, AUTOIMMUNE DISEASE; ANTICARCINOGENIC AGENTS WARNER-LAMBERT COMPANY 2004-01-13 — — US disclosed
EP-1210326-A2 HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-06-05 — — EP disclosed
WO-2001012592-A2 HYDROXAMIC ACID COMPOUNDS USEFUL AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172189-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA USP2 1658/4885HTT 2591/4885SMN1; SMN2 4285/4885
US-20130245018-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA USP2 1696/4885HTT 2680/4885SMN1; SMN2 4297/4885
US-20150266815-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA USP2 1696/4885HTT 2680/4885SMN1; SMN2 4297/4885
US-20160206578-A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use SOST, AADAC, ARSA USP2 1696/4885HTT 2680/4885SMN1; SMN2 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback